Journal
CELLS
Volume 10, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cells10051154
Keywords
FGFR; lung cancer; tyrosine kinase inhibitors; drug resistance
Categories
Funding
- Cancer Research UK [C36478/A19281]
- Rosetrees Trust
- Institute of Cancer Research (ICR)
Ask authors/readers for more resources
Lung cancer is the most common cause of cancer-related deaths globally, and genetic alterations in the FGFR family in non-small cell lung cancer play a role in cancer initiation and progression. Therapies targeting FGFR have been developed, but clinical trials have shown low efficacy in lung cancer patients with FGFR aberrations.
Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in non-small cell lung cancer (NSCLC) where they have a role in cancer initiation and progression. FGFR aberrations have also been identified as key compensatory bypass mechanisms of resistance to targeted therapy against mutant epidermal growth factor receptor (EGFR) and mutant Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) in lung cancer. Targeting FGFR is, therefore, of clinical relevance for this cancer type, and several selective and nonselective FGFR inhibitors have been developed in recent years. Despite promising preclinical data, clinical trials have largely shown low efficacy of these agents in lung cancer patients with FGFR alterations. Preclinical studies have highlighted the emergence of multiple intrinsic and acquired resistance mechanisms to FGFR tyrosine kinase inhibitors, which include on-target FGFR gatekeeper mutations and activation of bypass signalling pathways and alternative receptor tyrosine kinases. Here, we review the landscape of FGFR aberrations in lung cancer and the array of targeted therapies under clinical evaluation. We also discuss the current understanding of the mechanisms of resistance to FGFR-targeting compounds and therapeutic strategies to circumvent resistance. Finally, we highlight our perspectives on the development of new biomarkers for stratification and prediction of FGFR inhibitor response to enable personalisation of treatment in patients with lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available